

David Dodd/GeoVax
GeoVax Labs is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease program includes GEO-CM04S1, a next-generation Covid-19 vaccine designed for the growing population of high-risk immunocompromised patients with cancers, autoimmune conditions, and neuromuscular diseases. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. A synergistic program is underway with the rights from the US NIH to make GeoVax the first U.S. supplier of the vaccine vector MVA for protection against Monkeypox and Smallpox. GEO-CM04S1 GeoVax has a solid financial foundation, is listed on Nasdaq (“GOVX”), with a leadership team who have driven significant value creation across multiple life science companies over the past several decades.



Started in 2019, 

Born in January of 1947, the journey of Jerry Robb from birth to author of 12 books is an intriguing story in itself. He was born into a world-wide pandemic. Like the pandemic the world is experiencing today, polio was also viral. There was no vaccine. At age 5, polio hit where Robb lived in North Carolina, so he was sent to live with relatives in Georgia. It was there that Robb got his first taste of Aunt Kiki’s Bible. At age 10, he read the Book of Revelation with his cousin and has been hooked since.
When your veterinarian betrays your trust, 






Candidates make bold claims about issues they’ll support and oppose when elected. Sadly, most do not live up to their promises. 







Harper LeBel played tight end at Colorado State where he had 99 career receptions for 1,057 yards to finish 4th on the school’s all-time receiving list. He was drafted by the Kansas City Chiefs in 1985. He played 6 seasons with the Atlanta Falcons (1991-96) and also played for the Seattle Seahawks, Philadelphia Eagles, Chicago Bears and Baltimore Ravens during his 10 year NFL career. Harper currently serves as a studio analyst on the Atlanta Falcons Radio Network and is also part of the Georgia State football radio crew.


















